The Clinical Virology Team
Read about Patrik in the Research Portal
Senior Laboratory Assistant
Read about Sara in the Research Portal
" HIV research has always been very intriguing to me and this contributes to my long-term interest in the field. Working as a lab technician for three different groups gives me the opportunity to work with several projects with different aims and approaches. This equips me with a wide array of techniques and skills. I also have the privilege to train students with different academic backgrounds."
Ph.D. in virology
Since 2008, I'm involved in molecular epidemiology, drug resistance and evolution studies of Human Immunodeficiency, Hepatitis B and C viruses. From 2020, my research includes SARS-CoV-2 virus as well. My research interests has always been an integral part of practical health care. I believe the results of my research will help make the world a little healthier.
- HIV-1 single RNA reconstruction using BacBio deep sequencing
- SARS-CoV-2 molecular epidemiology in southern Skåne, Sweden
- SARS-CoV-2 airborne transmission
- HIV-1 molecular epidemiology in Belarus
Read about Sviataslau in the Research Portal
I did my PhD thesis work in the subject of clinical virology under the supervision of Professor Medstrand at Lund University and I graduated in 2017.
I wrote my PhD thesis on the utility of phylogenetic inference methods in the investigation of viral epidemiology and evolution. Before Lund, I studied Medicine at the University of Jordan followed by clinical training in the subject of clinical microbiology and immunology at Jordan University Hospital.
My current research looks at the molecular epidemiology of hepatitis and respiratory viruses in Jordan and the Middle East and North Africa region.
Email: malik [dot] sallam [at] ju [dot] edu [dot] jo
Born in 1946, M.D. in 1972, AW has a shared background in infectious diseases and clinical virology. Thesis in 1988 about cell culture of hepatitis A virus and hepatitis seroepidemiology. Established molecular detection of hepatitis C virus (HCV) RNA in 1990, allowing identification of candidates for antiviral treatment. In 1992 HCV genotyping and sequencing were developed as tools to follow transmission chains in nosocomial HCV infections e.g. children with cancer. Associate Professor in 1993. One strength at the Malmö virus lab was access to a huge serum bank collected since 1970 which allowed longitudinal studies of viral dynamics and introduction of new blood borne viruses. HCV was soon verified to be one of the major human carcinogenic viruses. With improved therapy and tracing of HCV infected people, often asymptomatic, the infection can now be eliminated and most of the cancer cases avoided. This is a WHO goal. AW has conducted such monitoring in hospital settings, among people who inject drugs and is now member of a CDC/WHO sponsored advisory group to eliminate HCV in the Republic of Georgia. AW has also applied molecular epidemiology for hepatitis A, B, HIV as well as gastrointestinal and respiratory viruses, mainly RNA viruses. The accumulated RNA experience collected over 4 decades has become highly useful during to ongoing Coivid-19 pandemic since several pathogenetic cellular mechanisms are shared between these RNA viruses. This allows AW to regularly give comprehensive updates to colleagues working with infectious diseases and/or basic research about SARS-CoV-2 and Covid-19
In the recent years an additional focus has been virus transmission by aerosols, work conducted with the Faculty of Engineering at Lund University
- Patrik Medstrand, PI
- Sara Karlson, Laboratory Technician
- Sviatasalau Sasinovich, Research Engineer
- Dawit Assefa, PhD student
- Malik Sallam
- Anders Widell